We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Genetic Test Enables Faster Diagnosis of Rare Diseases

By LabMedica International staff writers
Posted on 28 Nov 2025

Rare disease diagnosis often involves a long and uncertain search for the underlying genetic cause. More...

Traditional testing requires multiple separate analyses, although many patients remain without answers. A new clinical solution now offers a faster, more complete way to uncover hereditary conditions: a single test that maps the entire genome more accurately and captures complex variants that older methods miss.

The test, developed and implemented by Radboud University Medical Center (Nijmegen, Netherlands), in collaboration with Maastricht University Medical Center+ (Maastricht, Netherlands), is based on long-read genome sequencing, which measures DNA in much larger fragments and reconstructs all six billion building blocks with significantly higher completeness than short-read approaches. Radboudumc has now begun large-scale clinical use with 5,000 tests per year, initially targeting hereditary blindness and severe intellectual disabilities.

Study findings show that long-read sequencing increases diagnostic yield by more than ten percent for some rare diseases and can detect structural variations that are difficult to identify with conventional methods. The technique also captures DNA modifications that influence gene activity, offering deeper insight into disease mechanisms. Research suggests that ongoing analysis of these full-length genomes could raise the diagnostic uplift to as high as fifteen percent. Published evidence from genomic technology studies supports its suitability and reliability for routine clinical practice.

The introduction of this test is expected to replace around fifteen separate diagnostics, reduce time to diagnosis, and help uncover new hereditary causes of disease. For families, a definitive diagnosis brings clarity, emotional relief, and improved ability to connect with others facing similar conditions. Clinicians can also better assess future reproductive risk and provide more accurate prognostic information. As long-read sequencing becomes a new clinical standard, hospitals anticipate earlier answers and more comprehensive genetic insights for thousands of patients each year.

“Long read sequencing can replace fifteen other genetic tests in clinical practice, making diagnostics faster and more efficient,” said Professor of Genomic Technologies Alexander Hoischen. “I expect this will become the new standard for genome diagnostics and the only test we’ll perform in the future.”

Related Links:
Radboud University Medical Center
Maastricht University Medical Center+ 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.